Riemser Arzneimittel AG Invests in Swiss-based anwerinaAG
GREIFSWALD - Isle Of Riems, Germany and KREUZLINGEN, Switzerland, April 23, 2012 /PRNewswire/ --
RIEMSER Arzneimittel AG is extending its position as an international specialty pharmaceutical company by acquiring shares in the Swiss-based anwerina AG, a company specialised in the development and marketing of innovative drugs and medical devices in orthopaedics.
RIEMSER Arzneimittel AG and anwerina AG announce that RIEMSER is acquiring 49 % of the shares of the Swiss-based specialty pharmaceutical supplier in the osteology and surgical orthopedic sector, the successor of the former German subsidiary of Warner Chilcott and Procter & Gamble Pharmaceuticals. For RIEMSER, this is a further step towards strengthening its position as an international specialty pharmaceutical company focusing on high growth potential niche segments for high medical need.
anwerina AG, active in Germany since April this year, specialises in the marketing of innovative drugs and medical devices, especially for the treatment of osteoporotic and traumatic musculoskeletal diseases.
"I am very pleased that we found in anwerina AG a specialized company which, like RIEMSER, is focussing on a highly attractive market segment with products for which there is a high medical need and an enormous growth potential", explains Dr. Michael Mehler, CEO of RIEMSER Arzneimittel AG. "We are convinced that anwerina with its innovative products and its experienced team headed by Dr. Christoph Karl, who is an outstanding partner for us, will establish itself very successfully on the market", he added.
"We are delighted to have in RIEMSER Arzneimittel AG a strong industrial partner at our side to help us effectively and cost-efficiently improve the quality of life of patients with osteoporosis, arthrosis or vertebral fractures through innovative therapeutic approaches", comments Dr. Christoph Karl, CEO and Chairman of the Board of Directors of anwerina AG.
About anwerina AG: passion for patients
anwerina AG headquartered in Kreuzlingen, Switzerland, with its subsidiary anwerina Deutschland GmbH is an owner-managed pharmaceutical and medical device company specializing in the development and marketing of innovative drugs and medical devices for the pharmaceutical and surgical treatment of musculoskeletal diseases. anwerina focuses on metabolic bone diseases, cartilage replacement therapy and the minimal-invasive surgical treatment of vertebral compression fractures. anwerina is active in the German speaking markets Germany, Austria and Switzerland and operates from its base in Mannheim.
About RIEMSER Arzneimittel AG: A company with a tradition and a future
RIEMSER Arzneimittel AG with headquarters in Greifswald, Germany, is a mid-sized specialty pharmaceutical company which markets and distributes its products in Germany and 72 countries worldwide. RIEMSER focuses mainly on human prescription-only medicines in selected therapeutic niches with high medical need.
Core therapeutic areas cover supportive oncology, anti-infectives and dermatology. In its dental group RIEMSER provides solutions for oral regenerative, oral implant and oral healing medicine.
For further information please contact: http://www.riemser.com
anwerina AG, Mrs. Sabine Lau, Felsenburgweg 8, CH-8280 Kreuzlingen, Switzerland, sabine.lau@anwerina.com, Tel: +49-621-460793-40, Fax: +49 621-460793-41
RIEMSER Arzneimittel AG, Mrs. Claudia Kerber, An der Wiek 7, 17493 Greifswald-Insel Riems, http://www.RIEMSER.com, Tel.: +49-38351-76-129, Fax: +49-38351-7648, presse@riemser.de
Share this article